Pfizer, a major pharmaceutical company, has a 7.1% dividend yield, but its stock has dropped 55% since late 2022. The company faces challenges due to a shift in the public’s view of vaccines and upcoming patent expirations. Pfizer recently acquired Metsera for about $4.9 billion to bolster its drug pipelines.

Pfizer’s stock decline presents a turnaround opportunity, but caution is advised due to a high dividend payout ratio of 90% and past dividend cuts following acquisitions. The company must invest in new drugs to overcome patent cliffs and regain growth momentum. Consider other investment options as Pfizer may not be a secure dividend stock.

The Motley Fool’s Stock Advisor recommends 10 other stocks over Pfizer, citing potential for significant returns. Pfizer’s stock history and dividend payout ratio suggest income seekers should proceed with caution. The company’s long-term success hinges on strategic investments in new drugs and overcoming industry challenges.

Read more at Yahoo Finance: Down 55%, Should You Buy the Dip on Pfizer?